Wells Fargo & Company T Scan Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 306 shares of TCRX stock, worth $2,117. This represents 0.0% of its overall portfolio holdings.
Number of Shares
306
Previous 301
1.66%
Holding current value
$2,117
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TCRX
# of Institutions
67Shares Held
29.3MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$34.6 Million1.13% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$27 Million0.06% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$20.7 Million0.71% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$19.3 Million0.28% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$14.4 Million9.65% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $131M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...